Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EGFR Mutations in Head and Neck Squamous Cell Carcinoma.

International journal of molecular sciences - 30 Mar 2022

Nair Sindhu, Bonner James A, Bredel Markus

Abstract excerpt

EGFR is a prototypical receptor tyrosine kinase that is overexpressed in multiple cancers including head and neck squamous cell carcinoma (HNSCC). The standard of care for HNSCC remains largely unchanged despite decades of research. While EGFR blockade is an attractive target in HNSCC patients and anti-EGFR strategies including monoclonal antibodies and kinase inhibitors have shown some clinical benefit, efficacy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Cancer-related gene regulation
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Head and Neck Neoplasms

Share to Lung Cancer Treatments and Mutations

Share to Mutation

Share to Squamous Cell Carcinoma of Head and Neck

Source

Open in PubMed Open full text

Identifiers

PMID: 35409179
DOI: 10.3390/ijms23073818
PMCID: PMC8999014

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGFR Mutations in Head and Neck Squamous Cell Carcinoma.PMID 35409179Read ↗

Genetic alterations shaping tumor response to anti-EGFR therapies.Semantic proximity Read ↗

New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors.Semantic proximity Read ↗

Cracking the EGFR code: Cancer biology, resistance mechanisms, and future therapeutic frontiers.Semantic proximity Read ↗

HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells.Semantic proximity Read ↗

Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma (Review)Semantic proximity Read ↗

Epidermal growth factor receptor (EGFR) mutations as biomarker for head and neck squamous cell carcinomas (HNSCC).Semantic proximity Read ↗

Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck.Semantic proximity Read ↗

The quest to overcome resistance to EGFR-targeted therapies in cancer.Semantic proximity Read ↗

Molecular Aspects of Head and Neck Cancer Therapy.Semantic proximity Read ↗

Radiation resistance in head and neck squamous cell carcinoma: dire need for an appropriate sensitizerSemantic proximity Read ↗

Resistance of HNSCC cell models to pan-FGFR inhibition depends on the EMT phenotype associating with clinical outcome.Semantic proximity Read ↗

Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.